Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
- BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the third quarter ended September 30, 2024, before the financial markets open on Wednesday, November 6, 2024.
- 11/01/2024
|
Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?
- Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 10/04/2024
|
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
- Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.
- 09/04/2024
|
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
- BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present preclinical and clinical data from three of its epilepsy programs at the International League Against Epilepsy (ILAE) 15th European Epilepsy Congress (EEC), being held from September 7 to 11, 2024 in Rome, Italy.
- 09/04/2024
|
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
- Placebo-adjusted monthly motor seizure reduction of 46% during double-blind period Over 30% of patients achieved seizure freedom status while on relutrigine Meaningful gains observed in alertness, communication and seizure severity 75% reduction in median seizure rate seen for patients in the long-term extension Registrational phase of the EMBOLD study for SCN2A and 8A initiated BOSTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today shared positive topline results for its Phase 2, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients.
- 09/03/2024
|
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
- BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will share the topline results from the Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs) on Tuesday, September 3, 2024, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:00 a.m. ET to discuss the trial results.
- 09/02/2024
|
Praxis Precision Medicines (PRAX) Upgraded to Buy: What Does It Mean for the Stock?
- Praxis Precision Medicines (PRAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 08/15/2024
|
Praxis Precision Medicines, Inc. (PRAX) Q2 2024 Earnings and Corporate Update Call Transcript
- Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Marcio Souza - President and Chief Executive Officer Tim Kelly - Chief Financial Officer Daniel Ferry - Investor Relations, Life Science Advisors Conference Call Participants Yasmeen Rahimi - Piper Sandler Joon Lee - Truist Securities Francois Brisebois - Oppenheimer Yatin Suneja - Guggenheim Ritu Baral - TD Cowan Joel Beatty - Baird Ami Fadia - Needham Douglas Tsao - HC Wainwright & Co Kambiz Yazdi - Jeffries Operator Good day, thank you for standing by. Welcome to the Praxis Precision Medicines' Second Quarter 2024 Corporate Update Conference Call.
- 08/13/2024
|
Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates
- Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $1.74 per share versus the Zacks Consensus Estimate of a loss of $2.38. This compares to loss of $7.35 per share a year ago.
- 08/13/2024
|
Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
- BOSTON, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the second quarter ended June 30, 2024, before the financial markets open on Tuesday, August 13, 2024.
- 08/05/2024
|
Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
- Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 06/21/2024
|
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BOSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on June 3, 2024, the Compensation Committee of Praxis' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 300 shares of its common stock and restricted stock unit awards covering an aggregate of 225 shares of its common stock to one new non-executive employee under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”). The stock options and restricted stock units were granted as inducements material to the employee's entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
- 06/04/2024
|
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
- BOSTON, May 17, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming conferences.
- 05/17/2024
|
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively
- 05/13/2024
|
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
- BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will report financial results for the first quarter 2024 on Monday, May 13, 2024, before the U.S. financial markets open.
- 05/10/2024
|
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on May 1, 2024, the Compensation Committee of Praxis' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 7,800 shares of its common stock and restricted stock unit awards covering an aggregate of 5,851 shares of its common stock to six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The stock options and restricted stock units were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
- 05/03/2024
|
Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?
- The consensus price target hints at a 144.7% upside potential for Praxis Precision Medicines (PRAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 05/02/2024
|
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
- Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremor Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremor
- 04/12/2024
|
Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why
- Praxis Precision Medicines (PRAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 04/11/2024
|
Praxis Precision Medicines to Participate in Upcoming April Conferences
- BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will take part in upcoming conferences in April.
- 04/05/2024
|
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on April 1, 2024, the Compensation Committee of Praxis' Board of Directors granted non-qualified stock option awards to purchase 300 shares of its common stock and restricted stock unit awards covering 225 shares of its common stock to one new non-executive employee under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”). The stock options and restricted stock units were granted as inducements material to the employee's entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
- 04/02/2024
|
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
- BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 3,318,585 shares of its common stock at a public offering price per share of $56.50 and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 221,238 shares of common stock at a purchase price of $56.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. The gross proceeds from the offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis. All shares and pre-funded warrants in the offering are being offered by Praxis. In addition, Praxis has granted the underwriters a 30-day option to purchase up to 530,973 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 2, 2024, subject to market conditions and the satisfaction of customary closing conditions.
- 03/28/2024
|
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
- BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock. All securities in the offering will be offered by Praxis. In addition, Praxis intends to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount up to 15% of the shares of common stock (or prefunded warrants in lieu thereof) sold in the offering at the public offering price, less the underwriting discount and commission.
- 03/27/2024
|
Praxis (PRAX) Surges on Positive Epilepsy Study Results
- Praxis (PRAX) reports strong response rates across both study arms in a phase IIa proof of concept study for epilepsy patients with PPR.
- 03/27/2024
|
Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing
- Praxis Precision Medicines, Inc. results from the phase 3 Essential3 program, using ulixacaltamide for the treatment of patients with essential tremor, expected in the 2nd half of 2024. Company believes that the essential tremor U.S. market opportunity could be $4 billion. Positive data achieved in phase 2 study, using PRAX-628 for focal epilepsy; Phase 2b study targeting this very same patient population to be initiated 2nd half of 2024.
- 03/26/2024
|
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
- In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with prior dose escalation study and PK analysis confirmed therapeutic exposures Praxis plans to initiate an efficacy study in focal onset epilepsy in the second half of 2024 BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on its Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with PPR. PPR studies measure electroencephalogram (EEG) signatures after intermittent photic stimulation and are used as an indicator of anti-seizure efficacy.
- 03/26/2024
|
Praxis Precision Medicines to Host PRAX-628 Program Update
- Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at NYU Grossman School of Medicine BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will host a virtual program update to discuss its PRAX-628 program in epilepsy on Tuesday, March 26, 2024 at 8:00 a.m.
- 03/25/2024
|
What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now?
- Does Praxis Precision Medicines, Inc. (PRAX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 03/08/2024
|
Wall Street Analysts Think Praxis Precision Medicines, Inc. (PRAX) Could Surge 134.35%: Read This Before Placing a Bet
- The average of price targets set by Wall Street analysts indicates a potential upside of 134.4% in Praxis Precision Medicines, Inc. (PRAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 03/06/2024
|
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates
- Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.97 per share versus the Zacks Consensus Estimate of a loss of $3.15. This compares to loss of $13.04 per share a year ago.
- 03/05/2024
|
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
- Over 3,000 referrals received to date meet pre-qualifying eligibility criteria for ulixacaltamide Phase 3 studies in the Essential3 program for essential tremor (ET); enrollment on track to be completed in 1H 2024 with topline results in 2H 2024
- 03/05/2024
|
Praxis Precision Medicines to Participate in TD Cowen's 44th Annual Health Care Conference
- BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the TD Cowen 44th Annual Health Care Conference, taking place in Boston from March 4 – 6, 2024. In addition to conducting one-on-one investor meetings, management will participate in a corporate panel discussion.
- 03/01/2024
|
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BOSTON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on February 1, 2024, the Compensation Committee of Praxis' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 1,600 shares of its common stock and restricted stock unit awards covering an aggregate of 1,450 shares of its common stock to two new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”). The stock options and restricted stock units were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
- 02/02/2024
|
Praxis Precision Medicines, Inc. (PRAX) Just Flashed Golden Cross Signal: Do You Buy?
- After reaching an important support level, Praxis Precision Medicines, Inc. (PRAX) could be a good stock pick from a technical perspective. PRAX recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
- 01/05/2024
|
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
- BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside discussion at the Piper Sandler Healthcare Conference on November 28, 2023 at 10:00am. The event will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company's website at www.praxismedicines.com.
- 11/21/2023
|
Praxis Precision Medicines, Inc. (PRAX) Loses -32.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- The heavy selling pressure might have exhausted for Praxis Precision Medicines, Inc. (PRAX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 11/14/2023
|
New Strong Buy Stocks for October 11th
- PBF, PRAX, CPRX, MFA and GFF have been added to the Zacks Rank #1 (Strong Buy) List on October 11, 2023.
- 10/11/2023
|
Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
- BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be presenting analyses highlighting patient-focused endpoints from its Essential1 study of ulixacaltamide (PRAX-944) in essential tremor (ET) at The International Parkinson and Movement Disorder Society's (MDS) International Congress of Parkinson's Disease and Movement Disorders®, taking place in Copenhagen, Denmark.
- 08/28/2023
|
Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference
- BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will present at the 2023 Jefferies Healthcare Conference on Friday, June 9, 2023 at 8:00 a.m. ET.
- 06/02/2023
|
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
- BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its clinical stage programs at the upcoming American Academy of Neurology (AAN) 2023 Annual Meeting, held April 22-27, 2023 in Boston, Massachusetts.
- 04/19/2023
|
3 Hot Penny Stocks To Watch In The Stock Market Today
- Penny stocks to watch this week. The post 3 Hot Penny Stocks To Watch In The Stock Market Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/17/2023
|
Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference
- BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023 at 12:45 p.m. ET.
- 04/06/2023
|
Praxis Precision Medicines to Present at Upcoming Investor Conferences
- BOSTON, March 03, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the following upcoming investor conferences:
- 03/03/2023
|
Praxis: Shaking The Dust Off Calcium Channel Blockers For Essential Tremor
- Praxis Precision Medicines' ulixacaltamide (PRAX-944) is a potent and selective small molecule T-type Ca2+ channel blocker being developed for the potential treatment of essential tremor. ET is a common movement disorder affecting 4% of adults > 40. Current treatments like beta-blockers, anticonvulsants, and benzodiazepines are often ineffective or cause side effects, leaving patients with limited options.
- 03/03/2023
|
Praxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting
- BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the American Epilepsy Society (AES) 2022 Annual Meeting, held December 2-6, 2022 in Nashville, Tennessee.
- 11/28/2022
|
Praxis Precision Medicines to Present at Upcoming Investor Conferences
- BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the following upcoming investor conferences:
- 11/07/2022
|
Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference
- BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Wednesday, September 28, 2022 at 11:45 a.m. ET.
- 09/21/2022
|
Praxis Precision Medicines to Present at H.C. Wainwright 24th Annual Global Investment Conference
- BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 10:30 a.m. ET.
- 09/07/2022
|
Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline
- A phase 2/3 trial failure in the MDD indication of PRAX-114 allows this biotech to shift focus over to PRAX-944 for Essential tremors and other preclinical drugs. Results from the phase 2b Essential1 study using PRAX-944 for treatment of patients with essential tremors expected 2nd half of 2022; preliminary results already released from phase 2a study.
- 06/10/2022
|
Praxis (PRAX) Tanks on Negative Data From Depression Study
- Praxis (PRAX) posts negative data from the phase II/III Aria study that evaluated PRAX-114 for monotherapy treatment of major depressive disorder. Shares fall.
- 06/07/2022
|
Praxis Precision Posts Disappointing Data From Depression Study
- Praxis Precision Medicines Inc's (NASDAQ: PRAX) Phase 2/3 Aria Study of PRAX-114 for major depressive disorder (MDD) did not achieve statistical significance on the primary endpoint. The primary endpoint was the change from baseline in the total score of the 17-item Hamilton.
- 06/06/2022
|
Praxis Precision Medicines, Inc. (PRAX) - CEO Marcio Souza on Q1 2022 Earnings Call Transcript
- Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Marcio Souza – President and Chief executive Officer Bernard Ravina – Chief Medical Officer Alex Kane – Vice President Investor Relations and Corporate Communications Conference Call Participants Lauren Riaz – Piper Sandler Laura Chico – Wedbush Securities Yasmeen Rahimi – Piper Sandler Ritu Baral – Cowen & Company Myles Minter – William Blair Douglas Tsao – H.C. Wainwright Operator Good day and thank you for standing by.
- 05/09/2022
|
Praxis Precision Medicines to Provide Corporate Update and Report First Quarter 2022 Financial Results on Monday, May 9, 2022
- BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will provide a corporate update and report financial results for the first quarter 2022 on Monday, May 9, 2022, after the U.S. financial markets close. Management will provide a video update highlighting recent business and pipeline progress in conjunction with a press release. Subsequently, management will host a separate Q&A session via a live conference call and webcast at 4:30 p.m. ET.
- 05/02/2022
|
Praxis Precision Medicines to Present Data from PRAX-944 for Essential Tremor at 2022 American Academy of Neurology Annual Meeting
- BOSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that data from its PRAX-944 essential tremor (ET) program will be presented at the upcoming 2022 American Academy of Neurology (AAN) Annual Meeting, which will take place in Seattle, Washington from April 2 – 7, 2022 and virtually from April 24 – 26, 2022. Abstracts can be accessed on the AAN meeting website.
- 04/01/2022
|
Praxis Precision Medicines to Present at Stifel's 4th Annual CNS Day
- BOSTON, March 21, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at Stifel's 4th Annual CNS Day on Tuesday, March 29, 2022 at 11:30 a.m. ET.
- 03/21/2022
|
Praxis Precision Medicines, Inc. (PRAX) CEO Marcio Souza on Q4 2021 Results - Earnings Call Transcript
- Praxis Precision Medicines, Inc. (PRAX) CEO Marcio Souza on Q4 2021 Results - Earnings Call Transcript
- 02/28/2022
|
12 biotech stocks to consider buying now as prospects for the sector brighten this year
- Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double
- 02/06/2022
|
Praxis Precision Medicines to Present at Piper Sandler's 33rd Annual Virtual Healthcare Conference
- BOSTON, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in a fireside chat at Piper Sandler's 33rd Annual Virtual Healthcare Conference on Thursday, December 2, 2021 at 10:30 a.m. ET.
- 11/24/2021
|
Praxis Precision Medicines: Genetic Medicines For Neurological Disease
- Praxis is developing a potential first-in-class drug candidate, PRAX-114, in major depressive disorder. With clinical catalysts coming up in early 2022 for PRAX-114, there is a window of opportunity to invest in the company.
- 11/23/2021
|
Praxis Precision Medicines, Inc. (PRAX) CEO Marcio Souza on Q3 2021 Results - Earnings Call Transcript
- Praxis Precision Medicines, Inc. (PRAX) CEO Marcio Souza on Q3 2021 Results - Earnings Call Transcript
- 11/07/2021
|
Praxis Precision Medicines To Provide Corporate Update And Report Third Quarter 2021 Financial Results On Wednesday, November 3, 2021
- BOSTON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that it will provide a corporate update and report financial results for the third quarter 2021 on Wednesday, November 3, 2021, before the U.S. financial markets open. Management will discuss recent business and pipeline progress via a conference call and webcast at 8:30 a.m. ET.
- 10/22/2021
|
Praxis Precision Medicines to Present at Citi's 16th Annual BioPharma Virtual Conference
- CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in the ‘Emerging Therapies for Psychiatric Disorders' panel at Citi's 16th Annual BioPharma Virtual Conference on Wednesday, September 8, 2021 at 10:40 a.m. ET.
- 09/01/2021
|
BofA Initiates Praxis Precision Medical At Buy
- Praxis Precision Medicines Inc's (NASDAQ:PRAX) lead asset has demonstrated encouraging data for central nervous system diseases and has a broad pipeline that targets both prevalent and rare disorders, according to BofA Securities. The Praxis Precision Medical Analyst: Tazeen Ahmad initiated coverage of Praxis Precision Medical with a Buy rating and a price target of $28.
- 08/26/2021
|
Praxis Precision Medicines Reports PRAX-114 Perimenopausal Depression (PMD) Phase 2a Proof-of-Concept Trial Results and Announces Plans to Advance to Phase 2b Study in Women with Menopausal and Mood Symptoms
- PRAX-114 showed rapid and marked improvements in menopausal and mood symptoms in Phase 2a PMD study
- 08/16/2021
|
Praxis Precision Medicines to Present at 2021 Wedbush PacGrow Healthcare Conference
- CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in a fireside chat at the 2021 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10, 2021 at 9:10 a.m. ET.
- 08/02/2021
|
Praxis Precision Medicines to Present at Upcoming Investor Conferences
- CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences:
- 05/14/2021
|
Praxis Precision Medicines Prices Public Offering of Common Stock
- CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.25 per share. The gross proceeds to Praxis from the offering are expected to be approximately $91.25 million, before deducting the underwriting discounts and commissions and other offering expenses. Praxis has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock.
- 05/13/2021
|
Praxis Precision Medicines Announces Proposed Public Offering of Common Stock
- CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. Praxis also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. All shares in the offering are to be sold by Praxis. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
- 05/11/2021
|
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results
- Expands pipeline with new indications for PRAX-114 and PRAX-944
- 05/11/2021
|
PRAX Stock: From $32.22 To $28.40 Intraday Explanation
- The stock price of Praxis Precision Medicines (NASDAQ: PRAX) fell from $32.22 to a day low of $28.40 this morning as of 11:03 AM ET. This is why it happened.
- 04/30/2021
|
Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz, M.D.
- CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced the appointment of Jeffrey Chodakewitz, M.D., to its board of directors. The Company also announced that Nicholas Galakatos, Ph.D., and Kiran Reddy, M.D., have resigned from its board of directors.
- 04/15/2021
|
PRAX Stock: Over 15% Decrease Intraday Explanation
- The stock price of Praxis Precision Medicines Inc (NASDAQ: PRAX) fell by over 15% during intraday trading. This is why it happened.
- 04/14/2021
|
Praxis Precision Medicines to Present at Stifel's 3rd Annual CNS Day
- CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that management will participate in a fireside chat at Stifel's 3rd Annual CNS Day on Wednesday, March 31, 2021 at 8:30 a.m. ET.
- 03/24/2021
|
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
- PRAX-114 Phase 2/3 clinical trial for treatment of MDD to initiate in March 2021 following IND clearance
- 03/17/2021
|
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences:
- 11/20/2020
|
Praxis Precision Medicines Provides Update On PRAX-114 IND Submission For The Treatment Of Major Depressive Disorder
- - Praxis expects to initiate Phase 2/3 clinical trial for PRAX-114 in MDD in 1H21 -
- 11/17/2020
|
Praxis Precision Medicines Provides Regulatory Update On PRAX-114 Program
- CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that it has received a response from the U.S. Food and Drug Administration (FDA) on the Investigational New Drug (IND) submission for PRAX-114 for the treatment of major depressive disorder (MDD).
- 11/09/2020
|
